Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics, Inc. (IKT)
:IKT
IKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $4.20
Previous CloseN/A
Volume38.02K
Average Volume (3M)146.22K
Market Cap
$140.51M
Enterprise Value$127.99M
Total Cash (Recent Filing)$2.35M
Total Debt (Recent Filing)$209.49K
Price to Earnings (P/E)―
Beta1.58
Next Earnings
May 19, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding74,341,540
10 Day Avg. Volume167,225
30 Day Avg. Volume146,225
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)812.56
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.39
Forecast
1Y Price Target
$8.00Price Target Upside330.11% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Inhibikase Therapeutics News
PremiumCompany Announcements
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals
PremiumCompany Announcements
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO
PremiumCompany Announcements
Inhibikase Adjusts and Terminates Stock Offering Agreement---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentIkT-001Pro is being developed to address unmet needs in pulmonary arterial hypertension, representing a significant opportunity despite being a rare disease.
FDA ApprovalInhibikase received IND-clearance from the FDA for the Phase 2b 702 trial of IkT-001Pro in pulmonary arterial hypertension.
FundingInhibikase announced the closing of a private placement with gross proceeds of approximately $110M.
Bears Say
Analyst RatingAnalyst's rating downgraded to Neutral from Buy due to the company’s decision to halt further development of risvodetinib.
Earnings PerformanceInhibikase reported 4Q24 EPS of ($0.17), which was worse than the estimated ($0.10).
Product DevelopmentThe company halted further development of risvodetinib and there is no clinical data yet for IkT-001Pro in PAH, leading to a Neutral rating on the stock.
---
Ownership Overview
10.53% Insiders
0.13% Mutual Funds
66.08% Other Institutional Investors
19.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IKT FAQ
What was Inhibikase Therapeutics, Inc.’s price range in the past 12 months?
Inhibikase Therapeutics, Inc. lowest stock price was $1.12 and its highest was $4.20 in the past 12 months.
What is Inhibikase Therapeutics, Inc.’s market cap?
Inhibikase Therapeutics, Inc.’s market cap is $140.51M.
When is Inhibikase Therapeutics, Inc.’s upcoming earnings report date?
Inhibikase Therapeutics, Inc.’s upcoming earnings report date is May 19, 2025 which is in 37 days.
How were Inhibikase Therapeutics, Inc.’s earnings last quarter?
Inhibikase Therapeutics, Inc. released its earnings results on Mar 27, 2025. The company reported $0.88 earnings per share for the quarter, beating the consensus estimate of -$0.087 by $0.967.
Is Inhibikase Therapeutics, Inc. overvalued?
According to Wall Street analysts Inhibikase Therapeutics, Inc.’s price is currently Undervalued.
Does Inhibikase Therapeutics, Inc. pay dividends?
Inhibikase Therapeutics, Inc. does not currently pay dividends.
What is Inhibikase Therapeutics, Inc.’s EPS estimate?
Inhibikase Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Inhibikase Therapeutics, Inc. have?
Inhibikase Therapeutics, Inc. has 74,341,540 shares outstanding.
What happened to Inhibikase Therapeutics, Inc.’s price movement after its last earnings report?
Inhibikase Therapeutics, Inc. reported an EPS of $0.88 in its last earnings report, beating expectations of -$0.087. Following the earnings report the stock price went down -3.376%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics, Inc.?
Currently, no hedge funds are holding shares in IKT
---
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.00 (330.11% Upside)
$8.00 (330.11% Upside)
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.48%
12-Months-Change
Fundamentals
Return on Equity
-52.00%
Trailing 12-Months
Asset Growth
579.69%
Trailing 12-Months
Company Description
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company focused on developing therapeutics for the treatment of neurodegenerative diseases and viral infections. The company operates primarily in the biotechnology sector and aims to improve the lives of patients by leveraging its proprietary RAMP™ technology platform to discover and develop novel, disease-modifying therapies. Inhibikase's core product candidates include treatments targeting Parkinson's disease and other related disorders.
---
IKT Stock 12 Month Forecast
Average Price Target
$8.00
▲(330.11% Upside)
Technical Analysis
Best Analysts Covering IKT
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-2.80%
reiterated a buy rating 5 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -2.80% per trade.
---